Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches:
iPSC-derived, iMSC therapeutics
In vivo gene editing therapeutics
Complex human-derived mixed cytokines
April 15, 2022